Quick Answer
Autolus Therapeutics plc reported R&D Expense of $117.69 million for fiscal year 2025.
Autolus Therapeutics plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $117.69M | -15.0% |
| 2024 | $138.44M | +6.1% |
| 2023 | $130.48M | +11.2% |
| 2022 | $117.35M | +5.9% |
| 2021 | $110.84M | -17.8% |
| 2020 | $134.89M | +28.0% |
| 2019 | $105.42M | +191.6% |
| 2018 | $36.15M | +125.8% |
| 2017 | $16.01M | +53.4% |
| 2016 | $10.44M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.89M | -30.8% | +1.7% |
| June 30, 2025 | $27.43M | -25.1% | +2.6% |
| March 31, 2025 | $26.73M | -12.8% | -33.7% |
| September 30, 2024 | $40.32M | +24.8% | +10.1% |
| June 30, 2024 | $36.61M | +10.2% | +19.4% |
| March 31, 2024 | $30.67M | +12.0% | -5.1% |
| September 30, 2023 | $32.32M | -14.1% | -2.8% |
| June 30, 2023 | $33.23M | — | +21.3% |
- Autolus Therapeutics plc showed a decrease of -15.0% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Autolus Therapeutics plc’s r&d expense has grown by 1027.7% (from $10.44 million to $117.69 million).
- The most recent figure is from Autolus Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: